Prognostic Value of MicroRNA-20b in Acute Myeloid Leukemia

Frontiers in Oncology

Cong Deng¹  Yifeng Dai⁴  Lin Fu⁵  Longzhen Cui⁶  Yan Liu⁶  Zhihua Wu⁷  Tingting Qian⁷  Tiansheng Zeng⁷  Huoyan Zhu⁷  Qingfu Zhong⁷  Wenjuan Zhang⁷  Zhiheng Cheng⁷  Pei Zhu⁷  Qing Lin⁷  Wenhui Huang⁷ 

[1] Department of Clinical laboratory, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, China;Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands;Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China;Translational Medicine Center, Huaihe Hospital of Henan University, Kaifeng, China;Translational Medicine Center, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;

关键词: acute myeloid leukemia;    miR-20b;    allogeneic hematopoietic stem cell transplantation;    chemotherapy;    prognosis;   

DOI  :  10.3389/fonc.2020.553344

来源: DOAJ

【 摘 要 】

Acute myeloid leukemia (AML) is a highly heterogeneous disease that requires fine-grained risk stratification for the best prognosis of patients. As a class of small non-coding RNAs with important biological functions, microRNAs play a crucial role in the pathogenesis of AML. To assess the prognostic impact of miR-20b on AML in the presence of other clinical and molecular factors, we screened 90 AML patients receiving chemotherapy only and 74 also undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) from the Cancer Genome Atlas (TCGA) database. In the chemotherapy-only group, high miR-20b expression subgroup had shorter event-free survival (EFS) and overall survival (OS, both P < 0.001); whereas, there were no significant differences in EFS and OS between high and low expression subgroups in the allo-HSCT group. Then we divided all patients into high and low expression groups based on median miR-20b expression level. In the high expression group, patients treated with allo-HSCT had longer EFS and OS than those with chemotherapy alone (both P < 0.01); however, there were no significant differences in EFS and OS between different treatment subgroups in the low expression group. Further analysis showed that miR-20b was negatively correlated with genes in “ribosome,” “myeloid leukocyte mediated immunity,” and “DNA replication” signaling pathways. ORAI2, the gene with the strongest correlation with miR-20b, also had significant prognostic value in patients undergoing chemotherapy but not in the allo-HSCT group. In conclusion, our findings suggest that high miR-20b expression is a poor prognostic indicator for AML, but allo-HSCT may override its prognostic impact.

【 授权许可】

Unknown